Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta | Zendy

Heiner Wedemeyer | Zendy; Cihan Yurdaydìn | Zendy; George Ν. Dalekos | Zendy; Andreas Erhardt | Zendy; Yılmaz Çakaloğlu | Zendy; Halil Değertekin | Zendy; Selım Gürel | Zendy; Stefan Zeuzem | Zendy; Kalliopi Zachou | Zendy; Hakan Bozkaya | Zendy; Armin Koch | Zendy; C.Thomas Bock | Zendy; Hans Peter Dienes | Zendy; Michael P. Manns | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta

Author(s) -

Heiner Wedemeyer,

Cihan Yurdaydìn,

George Ν. Dalekos,

Andreas Erhardt,

Yılmaz Çakaloğlu,

Halil Değertekin,

Selım Gürel,

Stefan Zeuzem,

Kalliopi Zachou,

Hakan Bozkaya,

Armin Koch,

C.Thomas Bock,

Hans Peter Dienes,

Michael P. Manns

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0912696

Subject(s) - adefovir , medicine , virology , chronic hepatitis , gastroenterology , drug , hepatitis d , virus , hepatitis b virus , pharmacology , lamivudine , hbsag

Chronic infection with hepatitis B virus and hepatitis delta virus (HDV) results in the most severe form of viral hepatitis. There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research